<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04756661</url>
  </required_header>
  <id_info>
    <org_study_id>CARBOXMISO</org_study_id>
    <nct_id>NCT04756661</nct_id>
  </id_info>
  <brief_title>Uterotonics for Severe Preeclampsia</brief_title>
  <official_title>Carbetocin Versus Combined Oxytocin and Misoprostol for Prevention of Postpartum Hemorrhage in Women With Severe Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study compares the effect of Intravenous carbetocin versus combined use of intravenous&#xD;
      oxytocin and rectal misoprostol for prevention of postpartum hemorrhage during delivery of&#xD;
      women with severe preeclampsia&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">February 10, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of postpartum hemorrhage more than 1000 ml</measure>
    <time_frame>30 minutes</time_frame>
    <description>the amount of bleeding during and after CS</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Preeclampsia Severe</condition>
  <arm_group>
    <arm_group_label>Carbetocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient received 100 mcg of carbetocin intravenous over one minute immediately after delivery of the baby.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxytocin plus misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient received 10 units of oxytocin IV drip and 400 mcg of misoprostol rectally after anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbetocin</intervention_name>
    <description>100 mcg of Carbetocin intravenous injection</description>
    <arm_group_label>Carbetocin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>10 IU oxytocin IV drip</description>
    <arm_group_label>Oxytocin plus misoprostol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>400 mcg rectal</description>
    <arm_group_label>Oxytocin plus misoprostol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women which diagnosed with severe pre-eclampsia.&#xD;
&#xD;
          -  Singleton pregnancy.&#xD;
&#xD;
          -  Termination of pregnancy by Cesarean section after 28 weeks of gestation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Suspected or proven placental abruption.&#xD;
&#xD;
          -  Known placenta Previa or acreata.&#xD;
&#xD;
          -  Multiple pregnancies.&#xD;
&#xD;
          -  Obesity (BMI &gt;35).&#xD;
&#xD;
          -  Anemia (&lt;9 g/dl).&#xD;
&#xD;
          -  Retained placental tissues.&#xD;
&#xD;
          -  Big baby (&gt; 4 kg).&#xD;
&#xD;
          -  Presence of coagulopathy.&#xD;
&#xD;
          -  Polyhydramnios.&#xD;
&#xD;
          -  Presence of Uterine fibroids.&#xD;
&#xD;
          -  Medical diseases as; cardiac, liver, renal or endocrine diseases.&#xD;
&#xD;
          -  General anesthesia.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assiut Faculty of Medicine</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed Abbas</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Carbetocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

